Peptide Insider

Survodutide Side Effects: What the Trials Actually Measured

Survodutide side effects — what the trials actually measured

Written by Marcus Reinhardt · Lead Analyst, Peptide Insider · LinkedIn

Evidence-first peptide coverage — every claim on this page is linked to its primary source and reviewed against our editorial policy

Citations verified against PubMed · Published: 2026-09-04 · Last updated: 2026-09-07

Survodutide side effects have been measured in more people than almost any compound on the research market: a 725-person phase 3 in the New England Journal of Medicine, a 386-person phase 2 in The Lancet Diabetes & Endocrinology, two liver trials, and a diabetes study with a semaglutide arm — all placebo-controlled. The short answer: gastrointestinal effects in 80.9% to 89.7% of participants at the phase 3 doses versus 47.9% on placebo, vomiting as the column where survodutide separates from placebo hardest, and a glucagon component that explains why half the evidence is about the liver. This page gives you the actual rates, with citations, and flags where the trial data stops applying to a research vial.

Quick Answer: The Most Common Survodutide Side Effects

Gastrointestinal symptoms, by a wide margin. In the 76-week phase 3, GI adverse events — typically mild to moderate — occurred in 80.9% of the 3.6 mg group and 89.7% of the 6.0 mg group, versus 47.9% on placebo. The 48-week MASH phase 2 itemized them: nausea 66% vs 23%, diarrhea 49% vs 23%, vomiting 41% vs 4% for survodutide versus placebo. Serious adverse events in that trial were 8% with survodutide and 7% with placebo; the phase 3 reported no deaths. Self-reported experiences from Reddit are summarized further down; they are anecdotes, not data.

★The Documented Experience of 2,000+ Trial Participants

The most complete “user experience” of survodutide that exists belongs to the people who took it under observation — 725 in the phase 3 obesity trial, 386 in the phase 2, 293 in the MASH trial, 216 in the MASLD phase 3, and 411 in the diabetes study. The typical arc: a dose-escalation period measured in months, gastrointestinal symptoms clustering inside it, and weight moving steadily downward — 12.2% to 13.0% at 76 weeks in the phase 3, against 5.4% on placebo.

How tolerable did participants find it? The Lancet phase 2 investigators’ verdict: “all tested survodutide doses were tolerated” — with the footnote that 60.4% completed the 46 weeks, the same on placebo (60%) as on survodutide (61%). Placebo groups reported GI complaints too — 47.9% in the phase 3 — a baseline most online discussion never subtracts.

What that experience came with: screening, monitoring, pharmaceutical-grade product from Boehringer Ingelheim, clinician-managed escalation — none of which ships with a research vial.

Compiled from the published trials (PMID 42253238, PMID 38330987, PMID 38847460, PMID 42252333, PMID 38095657) — not from testimonials. When we publish an individual account here, it will be a real person, named with permission.

Research peptide vial

Looking for Lab-Tested Peptides?

Our top-rated vendor publishes batch COAs and third-party testing on every compound — get up to 30% off your first order.

Shop Amino Club →

Affiliate link — it doesn’t change what we report. All compounds sold strictly for non-human research use. Read our full Amino Club review.

In This Guide

What Is Survodutide?

Survodutide (Boehringer Ingelheim’s BI 456906, licensed from Zealand Pharma) is a once-weekly subcutaneous glucagon receptor/GLP-1 receptor dual agonist (PMID 38330987, PMID 42252333). That second receptor separates it from the single-target GLP-1 class, and it is why the program runs on two tracks: obesity and fatty liver disease. In the 76-week phase 3, doses adjusted up to 3.6 mg or 6.0 mg produced 12.2% and 13.0% average weight loss versus 5.4% on placebo (PMID 42253238). It remains investigational — not approved anywhere as of this writing — so everything sold under this name outside a trial is research-market material.

How It Works — and Why the Glucagon Half Matters

The GLP-1 half does what every GLP-1 agonist does — slows gastric emptying, dampens appetite — and the gastrointestinal side effects on this page are that mechanism turned up. The glucagon half is the design bet: it pushes the liver toward burning fat and raises energy expenditure, which is why the compound went into a MASH trial on the hypothesis that dual agonism “may be more effective than GLP-1 receptor agonism alone” (PMID 38847460). Glucagon also raises hepatic glucose output — the reason a type 2 diabetes trial measured HbA1c before anyone worried about weight (PMID 38095657).

KEY TAKEAWAY

Survodutide’s side effects read like GLP-1-class side effects at the high end of the range: gastrointestinal, dose-related, concentrated during escalation. The glucagon component’s fingerprints — heart rate, glucose — are not itemized in any abstract we can cite. Absence of reporting, not evidence of absence.

The Trial Numbers That Matter

Five placebo-controlled datasets carry this page. The phase 2 obesity trial: 386 treated, randomized to 0.6, 2.4, 3.6, or 4.8 mg weekly or placebo for 46 weeks — 20 of escalation, 26 of maintenance (PMID 38330987). The phase 3 SYNCHRONIZE-1 trial: 725 adults (241 at 3.6 mg, 242 at 6.0 mg, 242 on placebo) over 76 weeks; weight change -12.2%, -13.0%, and -5.4%, with 72.6%, 71.9%, and 46.3% losing at least 5% (PMID 42253238). The MASH phase 2: 293 adults with biopsy-confirmed MASH on 2.4, 4.8, or 6.0 mg or placebo for 48 weeks (PMID 38847460). The SYNCHRONIZE-MASLD phase 3: 216 adults with obesity and at-risk fatty liver, randomized 2:1 to 6.0 mg (n=146) or placebo (n=70) for 48 weeks (PMID 42252333). And the type 2 diabetes phase 2: 413 randomized across six survodutide dose groups, placebo, and open-label semaglutide for 16 weeks (PMID 38095657).

Gastrointestinal Side Effects: The Real Rates

In the phase 3, gastrointestinal symptoms — “typically mild to moderate” — were the most common adverse events: 80.9% of the 3.6 mg group, 89.7% of the 6.0 mg group, 47.9% of the placebo group (PMID 42253238). The phase 2 reported the same shape: adverse events in 281 (91%) of 309 survodutide recipients versus 58 (75%) of 77 on placebo, “primarily gastrointestinal” in 232 (75%) of 309 versus 32 (42%) of 77 (PMID 38330987). Neither obesity abstract breaks GI events down by symptom.

The MASH trial does: nausea (66% vs 23%), diarrhea (49% vs 23%), vomiting (41% vs 4%) for survodutide versus placebo (PMID 38847460) — a liver-disease population on a rapid 24-week escalation. The diabetes trial adds adverse events in 77.8% of survodutide-treated participants, “mainly gastrointestinal,” versus 52.5% on placebo and 52.0% on open-label semaglutide (PMID 38095657). The MASLD abstract gives no rate, calling GI events the most frequent and “generally of mild-to-moderate severity” (PMID 42252333).

PERSONAL OBSERVATION — PI EDITORIAL

Reading these five trials side by side, what struck us wasn’t the survodutide column — it was the placebo column. GI complaints on placebo ran 47.9% in the phase 3, 42% in the phase 2, 23% for nausea in the MASH trial. Gut symptoms are the background noise of obesity trials; survodutide’s attributable share is the gap above that noise. The one place the gap is unmistakable is vomiting: 41% against 4%.

Bar chart from the survodutide MASH phase 2 trial, pooled survodutide doses versus placebo over 48 weeks: nausea 66% vs 23%, diarrhea 49% vs 23%, vomiting 41% vs 4%.
Chart: gastrointestinal adverse events in the 48-week MASH phase 2, survodutide arms pooled as the abstract reports them, versus placebo (PMID 38847460). Serious adverse events were 8% versus 7%. Population: biopsy-confirmed MASH with F1–F3 fibrosis — not a general-obesity cohort.

Vomiting and Completion: The Two Numbers Worth Reading Twice

The first is vomiting: 41% with survodutide versus 4% with placebo in the MASH phase 2 (PMID 38847460). Nausea and diarrhea carried substantial placebo rates (23% each); vomiting did not, making it the cleanest drug-attributable GI signal in any survodutide abstract. The population caveat applies — biopsy-confirmed MASH, a 24-week rapid escalation — and neither obesity abstract itemizes vomiting.

The second is completion. In the 46-week phase 2, 233 (60.4%) of 386 participants completed treatment — 187 (61%) of 309 on survodutide, 46 (60%) of 77 on placebo (PMID 38330987). Identical completion on placebo means the dropout is not, on this evidence, a tolerability story; the trial enrolled in 2021 and censored COVID-19-related discontinuations. No abstract reports discontinuation due to adverse events, so neither do we. Anyone quoting “40% quit because of side effects” invented the causation.

Injection-Site Reactions

The abstracts do not report injection-site reaction rates. Neither obesity abstract names administration-site events among the common adverse events (PMID 42253238, PMID 38330987), nor does either liver abstract. That tells you they weren’t a leading category, and nothing more precise. Survodutide is a once-weekly subcutaneous injection in every trial cited here, so the standard handling picture applies.

PRACTICAL NOTES — STANDARD SUBCUTANEOUS HANDLING

  • Reconstituted solutions brought to room temperature before use are standard practice in clinical settings
  • Site rotation (abdomen, thigh, upper arm) is how trial protocols manage repeated weekly injections
  • Sterile technique — clean site, single-use needles — is non-negotiable in any protocol, trial or lab
  • Our bacteriostatic water guide covers reconstitution handling in detail

Beyond the Gut: What Else the Trials Recorded

On the serious end, the numbers are reassuring and thin. The MASH trial reported serious adverse events in 8% with survodutide and 7% with placebo (PMID 38847460); the phase 3 reported no deaths (PMID 42253238). What the abstracts don’t itemize is what a glucagon agonist prompts a pharmacologist to ask about — heart rate, glucose excursions, liver enzymes — and their absence means they didn’t make the most-common lists, not that they were found clean. One indirect glucose signal exists: in the diabetes trial, HbA1c fell in every survodutide group, the low-dose reduction (-1.46%) matching open-label semaglutide’s (-1.47%) (PMID 38095657) — the glucagon half did not visibly undercut glycemic control over 16 weeks. Cardiovascular outcome data appears in none of the cited abstracts; we won’t convert absence into a safety claim.

What Users Report: Self-Reported Effects From Reddit

The trials above answer the frequency question well; what they cannot describe is how almost everyone on Reddit uses survodutide: as a research vial added to tirzepatide after a stall near its maximum dose. We searched Reddit on September 5, 2026, found 62 relevant posts from 2025 to 2026, and read the comment threads of ten, all of them in r/survodutide. Everything below is paraphrased and linked, uses no usernames, and describes products nobody verified. Two caveats: nearly every gray-market report is a stack, so nobody can say which drug did what, and at least three posters are self-described clinical-trial participants on blinded Boehringer product.

Energy is the effect people come for, and fatigue is the one that surprises them. At least five posters describe more energy: a woman who replaced a tirzepatide microdose with survodutide had no racing thoughts and, to her surprise, energy (r/survodutide); a poster who added 0.3 mg to max-dose tirzepatide felt a lift on shot days (thread); another called the stack excellent for energy (thread). Three others describe the opposite: first-week exhaustion; early energy turning into really bad fatigue at a higher dose; and extreme afternoon sleepiness the day after each shot, which one warned can take months to lift (all r/survodutide).

Gut complaints are milder here than in the trials, and nobody describes vomiting. People report reflux, burping and early constipation, and a day of mild nausea and sulfur burps after each dose increase (both thread); a touch of nausea on the first shots, and occasional stomach trouble from a trial participant a year in (both thread). The one person who quit over the gut had opened at 2.4 mg where most describe 0.3, and four months later could not shake a sour stomach tirzepatide alone never gave him (r/survodutide).

Slow response and felt-nothing reports are as common as success stories. One poster said survodutide did nothing until 1.2 mg; in the same thread one person felt nothing from two 0.3 mg doses and another nothing until 1 mg (r/survodutide). A blinded trial participant losing a pound a month called themself a non-responder and listed headaches, constipation and nausea (thread). Others describe little or no side effect: the Monday-tirzepatide, Thursday-survodutide poster who broke a stall on 1.8 mg and reached goal (r/survodutide), and a self-described safety-trial participant who reported losing 110 pounds (thread).

The heart-rate reassurance is a belief, not a measurement. Many posters fled retatrutide: one described anxiety, impending doom and Adderall-like overstimulation on it and none on survodutide (thread; see our retatrutide side effects page). Two posters say survodutide did not raise their resting heart rate, one contrasting it with a 12 to 15 beat rise on tirzepatide (thread, thread), and a third believes it the only dual agonist that spares heart rate. Another thread contests that, noting the glucagon receptor is the component most expected to raise heart rate (r/survodutide). Nobody reports measuring it; a high-blood-pressure question drew two opinions and no experience (thread).

The rest are single, confounded reports: hair thinning in a trial participant who noted they skimp on protein (thread); a flu-like illness after a first shot that drew no matching reports (thread); and a flat, indifferent mood in a poster who later moved to retatrutide and cagrilintide (thread).

HOW TO READ SELF-REPORTS

The trials say vomiting is where survodutide separates from placebo hardest; ten Reddit threads contain no vomiting report. That is selection, not reassurance: the posters are stackers who stayed on long enough to write, at self-chosen doses, using a product one trial participant calls fake. Fatigue, the most-discussed effect here, is not a headline trial finding, and neither source can say what two incretin agonists do together; no trial tested it.

When Side Effects Happen — and When They Fade

No published survodutide data supports a week-by-week side-effect calendar, and anyone offering one made it up. What the designs do tell you: every trial front-loaded a long escalation. The phase 2 ran 20 weeks of escalation before 26 of maintenance (PMID 38330987); the MASH trial ran a 24-week “rapid-dose-escalation phase” before 24 weeks of maintenance (PMID 38847460). The MASLD authors state the pattern outright — GI events “commonly occurring during dose escalation” (PMID 42252333) — and the diabetes-trial authors concluded that “dose-related gastrointestinal AEs could be mitigated with slower dose escalations” (PMID 38095657). Each new exposure level is the risky window, and the trials spent roughly their first half inside it on purpose. Fade-out on maintenance is not quantified in any abstract.

Long-Term Safety: What 76 Weeks Can and Can’t Tell You

The longest published exposure is the phase 3’s 76 weeks in 725 people, with no deaths (PMID 42253238). Behind it sit the 48-week liver trials (PMID 38847460) and the 46-week phase 2, whose investigators concluded “all tested survodutide doses were tolerated” (PMID 38330987). That is meaningful reassurance across the first year and a half, and also the entire horizon; the MASLD authors listed “short trial duration (48 weeks)” among their own limitations (PMID 42252333). Multi-year safety data doesn’t exist because it can’t yet. Anyone describing a five-year profile is forecasting, not reporting.

Who the Trials Excluded

Trial numbers describe trial populations. The phase 3 enrolled adults with a BMI of 30 or higher, or 27 or higher with a complication — excluding diabetes; its typical participant was 47.1 years old with a BMI of 37.9 and a weight of 108.8 kg, and 40.6% were men (PMID 42253238). The phase 2 enrolled adults aged 18–75 with a BMI of 27 or higher, also without diabetes (PMID 38330987). The MASH trial required biopsy-confirmed steatohepatitis with F1–F3 fibrosis (PMID 38847460); the MASLD phase 3 recruited in the United States and Spain only (PMID 42252333); the diabetes trial ran on background metformin (PMID 38095657). Every rate here was generated in screened, monitored people — a context no research buyer replicates.

Managing and Minimizing Side Effects: What the Trials Did

The trials’ side-effect management was structural: escalation design. The diabetes-trial authors put it in a sentence — “dose-related gastrointestinal AEs could be mitigated with slower dose escalations” (PMID 38095657) — and later trials acted on it, with 20 weeks of escalation in the phase 2 (PMID 38330987) and “a prolonged dose-escalation period” in the phase 3 (PMID 42253238). The other lever is dose ceiling: the phase 3’s 3.6 mg arm reported GI events in 80.9% versus 89.7% at 6.0 mg while landing within a point of it on weight. No anti-nausea co-medication appears in any abstract. We report this as trial design, not a recommendation — and the compound with the most direct escalation-versus-none comparison is MariTide, whose phase 2 randomized participants to both.

Dose and Side Effects: The Correlation Is Measured

Survodutide’s dose–response has been plotted across three designs. In the phase 2, weight loss climbed from -6.2% at 0.6 mg through -12.5% and -13.2% to -14.9% at 4.8 mg — the compound “dose-dependently reduced bodyweight” (PMID 38330987). In the phase 3, the two doses were nearly indistinguishable on weight (-12.2% versus -13.0%) but not on GI events (80.9% versus 89.7%) (PMID 42253238): the higher dose bought more side effect than effect. The MASH trial is the outlier. Histologic improvement without fibrosis worsening occurred in 47% at 2.4 mg, 62% at 4.8 mg, and 43% at 6.0 mg versus 14% on placebo — a quadratic dose-response, with the middle dose doing best (PMID 38847460). Liver fat reduction of at least 30% followed the same arc: 63%, 67%, 57%, and 14%. The abstract doesn’t explain why, and we won’t guess. The family pattern holds: exposure buys effect and side effect together, and past some point only the latter.

DID YOU KNOW

The diabetes phase 2 tested survodutide twice weekly as well as once weekly — 1.2 mg and 1.8 mg twice-weekly arms alongside 0.3 to 2.7 mg once-weekly — and its largest weight loss, -8.7% at 16 weeks, came from the 1.8 mg twice-weekly group (PMID 38095657).

Survodutide Alone vs Stacked: What the Data Covers

Survodutide is itself the stack: one molecule built to hit two receptors, the pharmaceutical answer to hand-built stacks. Every published rate here comes from survodutide alone — the phase 3 added only “counseling for lifestyle modification” (PMID 42253238). No trial has tested survodutide combined with any other incretin or amylin compound. The stacks research forums already discuss — survodutide plus retatrutide, plus an amylin analogue like cagrilintide — have no published human safety data; layering a glucagon agonist onto a triple agonist that already contains one is pharmacology nobody has measured. Our GLP-3 sourcing guide covers that family.

How Survodutide Compares to Semaglutide, Retatrutide, and Mazdutide

Survodutide has what most compounds on this site lack: a within-trial active comparator. In the 16-week diabetes phase 2, open-label semaglutide (up to 1.0 mg weekly) produced -5.3% weight loss with adverse events in 52.0%; survodutide’s highest-exposure group (1.8 mg twice weekly) produced -8.7%, with adverse events in 77.8% across all survodutide arms (PMID 38095657). Same trial, same population — more weight loss, more side effects, and an HbA1c effect the low dose matched almost exactly (-1.46% versus -1.47%). The asymmetry: semaglutide was open-label and capped at 1.0 mg.

Everything else is cross-trial — different populations, durations, and reporting conventions. With that flag planted, survodutide’s phase 3 GI rate of 80.9–89.7% versus 47.9% on placebo sits alongside mazdutide side effects (the other glucagon/GLP-1 dual agonist) and retatrutide side effects (the triple agonist that adds GIP), while MariTide blocks GIP and doses monthly. Survodutide’s distinctive entry is the liver: the only compound in this cluster with biopsy-confirmed MASH results — 62% histologic improvement at 4.8 mg versus 14% on placebo (PMID 38847460).

Where the Trial Data Stops: The Research-Vial Reality

Everything above describes pharmaceutical-grade BI 456906, made under Boehringer Ingelheim’s quality system and dosed by clinicians on a months-long escalation. A lyophilized vial from a research-chemical storefront shares a molecule name with that product and nothing else verifiable without testing. The gap shows up three ways: identity and purity (a batch-matched COA is the only evidence the vial contains dose-accurate survodutide — see our lab-testing guide), concentration arithmetic (reconstitution with bacteriostatic water is on the buyer; our peptide calculator handles the math, deliberately nothing else), and no medical monitoring, the invisible ingredient in every trial safety table. Compounds in this channel are sold strictly for non-human research use.

Sourcing and Verification

Survodutide listings now quote phase 3 numbers. The checklist doesn’t change: batch-matched COA naming the compound and quantity, third-party testing with a verifiable report number, and hard skepticism toward any listing quoting the trials’ 13.0% or 14.9% as if they applied to the vial. (Disclosure: some links on this site are affiliate links; they don’t change what we report.) Our vendor directory and Amino Club review show what passing documentation looks like, and our guide library covers verification in depth. When our tested vendors stock it, this section gets a live price table.

US Regulatory Status

Survodutide is investigational — the NEJM phase 3 authors’ own word — with no FDA approval as of this writing and the SYNCHRONIZE phase 3 program still running across obesity and liver disease (PMID 42253238, PMID 42252333). Practically, no prescription version exists, every vial in circulation is research-market material sold for non-human research use, and no regulator has evaluated those products for identity, purity, or safety. When approval status changes, this section changes with it.

PERSONAL OBSERVATION — PI EDITORIAL

In the survodutide listings we’ve reviewed, the pattern is the phase 2’s -14.9% pasted into a product description and the phase 3’s 89.7% GI rate nowhere in sight. Both came from the same compound; a reader who sees only one has been sold something. The trials spent 20 to 24 weeks climbing to their doses under supervision; the vial comes with a concentration and no calendar. Until third-party results on market product circulate, the COA is the only sentence of this page that applies to the one in your hand.

Frequently Asked Questions

What are the most common survodutide side effects?

Gastrointestinal symptoms. In the 76-week phase 3, GI adverse events occurred in 80.9% (3.6 mg) and 89.7% (6.0 mg) versus 47.9% on placebo. The MASH phase 2 itemized them: nausea 66% vs 23%, diarrhea 49% vs 23%, vomiting 41% vs 4%.

Does survodutide cause vomiting?

In the 48-week MASH phase 2, vomiting was reported in 41% of survodutide participants versus 4% on placebo — the cleanest drug-attributable signal in any survodutide abstract. The obesity abstracts don’t itemize it.

How many people finished the survodutide trials?

In the 46-week phase 2 obesity trial, 233 (60.4%) of 386 participants completed treatment — 61% on survodutide and 60% on placebo. Same completion in both arms means the dropout cannot be attributed to drug tolerability; no abstract reports discontinuation due to adverse events.

How much weight did people lose on survodutide?

In the phase 3, -12.2% at 3.6 mg and -13.0% at 6.0 mg over 76 weeks versus -5.4% on placebo. The phase 2 ranged from -6.2% to -14.9% by dose over 46 weeks versus -2.8% on placebo.

Is survodutide safe?

In trials, serious adverse events were 8% with survodutide versus 7% with placebo (MASH phase 2), no deaths were reported in the 725-person phase 3, and the phase 2 investigators concluded all tested doses were tolerated — in monitored populations for at most 76 weeks. No such data exists for research-market vials.

How does survodutide compare to semaglutide?

The only head-to-head data is the 16-week diabetes phase 2: open-label semaglutide (up to 1.0 mg) produced -5.3% weight loss with adverse events in 52.0%; survodutide’s highest-exposure group (1.8 mg twice weekly) produced -8.7%, with adverse events in 77.8% across all survodutide arms.

Glossary of Terms

  • Dual agonist: a single molecule that activates two receptors — here glucagon and GLP-1 — rather than a combination of two drugs.
  • BI 456906: Boehringer Ingelheim’s development code for survodutide; the compound was licensed from Zealand Pharma.
  • Glucagon receptor: the target that distinguishes survodutide from plain GLP-1 agonists; activation increases hepatic fat burning and energy expenditure.
  • MASH: metabolic dysfunction-associated steatohepatitis — fatty liver disease with inflammation, biopsy-confirmed in the phase 2 liver trial.
  • Dose escalation: raising the dose stepwise so tolerance develops; survodutide trials devoted 20 to 24 weeks to it.
  • Treatment-regimen estimand: an analysis counting everyone as randomized, including those who stopped treatment — which makes the phase 3’s figures conservative.
  • COA (certificate of analysis): the lab document identifying a research vial’s contents; batch-matched or it proves nothing.

References